Argent BioPharma Limited

As of June 30, 2024, Argent BioPharma Limited has 45.28M shares outstanding.

As of June 30, 2024, Argent BioPharma Limited maintains a current ratio of 0.23, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -17.94, indicating conservative leverage, while an interest coverage ratio of -37.85 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -168.80, reflecting losses generated across the asset base. Inventory turnover of 0.61 indicates how many times Argent BioPharma Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, Argent BioPharma Limited posted a gross margin of 22.86, reflecting its pricing power and cost economics. The operating margin of -2,049.40 and net profit margin of -1,967.34 provide insight into operational efficiency.

Argent BioPharma Limited's most recent stock split took place on November 2, 2023 with a 1000:1 split ratio.

As of June 30, 2024, Argent BioPharma Limited has an Altman Z-Score of -23.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.